Therapeutic Response

PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Cisplatin in combination with Fluorouracil and Pembrolizumab in patients with Esophageal Adenocarcinoma.

View API

Statements

Source and description

View API